テネシーにおける膠腫の臨床試験
テネシー内の拠点で、膠腫に関する8件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- St. Jude Children's Research Hospital, Memphis
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05916313A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
- Vanderbilt University Medical Center, Nashville
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/07/01更新 · NCT07210632Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
- St. Jude Children's Research Hospital, Memphis
被験者募集中第2相
3歳以下 · 全性別 · 2026/05/13更新 · NCT06528691A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06326411ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。